A report has cast doubts on the manner in which drugs are released into the market, faster than ever before, raising concerns about patients' safety.
Author David Kao, from the University of Colorado Health Sciences Center, says that the pressure on drug regulatory bodies to make new medicines available more quickly has raised fresh concerns about patients' safety.
Patient Safety Should Be Top Priority While Prescribing Medications: AMA
Doctors must maintain sole responsibility for prescribing medication to patients, AMA President, Dr Rosanna Capolingua said today.
Advertisement
He reviewed trends in drug approval times in the U.S., and came up with suggestions as to how marketing techniques could be used to improve the way new medicines were monitored.
Publishing his report in the online edition of the British Medical Journal (BMJ), he has highlighted the fact that marketing techniques these days are so sophisticated that once a drug has been approved, the products can be released on websites within 90 minutes.
He even points out how 188 million patients had been targeted by the marketing campaign within 14 days after Merck's new treatment for high blood sugar levels, sitagliptin, was approved.
Kao thinks that a large number of patients may be exposed to unknown risks if people try any new medicine so quickly.
The reviewer also says that regulatory agencies often depend on drug companies for funding, and collect fees so as to hire staff to review new medicines more quickly.
He recommends improvement in the systems for reporting adverse drug reactions, and the use of the very same effective drug marketing techniques to do so.
Kao says that U.S. laws already compel TV adverts to instruct patients experiencing negative side effects to report their symptoms to the FDA, and this could be expanded to include campaigns dedicated to drug safety monitoring.
According to him, the only drug monitoring system that will minimise unknown risks must involve all the key players in healthcare, including doctors, regulatory bodies, drug companies and patients.
Source: ANI
SAV/SK
Advertisement
He even points out how 188 million patients had been targeted by the marketing campaign within 14 days after Merck's new treatment for high blood sugar levels, sitagliptin, was approved.
Kao thinks that a large number of patients may be exposed to unknown risks if people try any new medicine so quickly.
The reviewer also says that regulatory agencies often depend on drug companies for funding, and collect fees so as to hire staff to review new medicines more quickly.
He recommends improvement in the systems for reporting adverse drug reactions, and the use of the very same effective drug marketing techniques to do so.
Kao says that U.S. laws already compel TV adverts to instruct patients experiencing negative side effects to report their symptoms to the FDA, and this could be expanded to include campaigns dedicated to drug safety monitoring.
According to him, the only drug monitoring system that will minimise unknown risks must involve all the key players in healthcare, including doctors, regulatory bodies, drug companies and patients.
Source: ANI
SAV/SK
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
